Business Context and Reporting Period
Company: Anteris Technologies Global Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: November 17, 2025
Reporting Period: Event-based disclosure regarding clinical outcomes announced on November 16, 2025 (ASX) and November 17, 2025 (Press Release).
The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Toowong, Australia. It is listed on The Nasdaq Global Market under the symbol "AVR".
Key Financial Metrics
This filing is a Regulation FD disclosure regarding clinical trial results and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material event reported is the presentation of 30-day clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV). The data covers one hundred severe aortic stenosis patients with small aortic annuli. This information was presented at the PCR London Valves conference.
Guidance, Outlook, and Risks
Management Commentary: The Company issued an ASX Announcement and a press release to disseminate the clinical data. No specific forward-looking guidance, financial outlook, or risk factors were detailed within the text of this specific 8-K filing beyond the standard regulatory disclaimers.
Regulatory Note: The information furnished in this report shall not be deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into any filing under the Securities Act or Exchange Act unless specifically referenced in a subsequent filing.
Investor Verification Checklist
- Verify the full text of the ASX Announcement and Press Release (Exhibit 99.1) for detailed clinical data points not summarized in the 8-K.
- Confirm the specific success rates and safety metrics for the 100-patient cohort with small aortic annuli.
- Review subsequent filings to determine if this data triggers any updates to regulatory approval timelines or commercialization plans.
- Check for any financial impact analysis in future quarterly reports (10-Q/10-K) related to the clinical trial costs or potential revenue implications.